NON SMALL CELL CARCINOMA- LUNG: DISTRIBUTION AND SPECTRUM OF MUTATIONS AMONG PATIENTS IN EASTERN INDIA

A. Islam, M. Mondal, C. Datta, U. Chatterjee, A. Dastidar
{"title":"NON SMALL CELL CARCINOMA- LUNG: DISTRIBUTION AND SPECTRUM OF MUTATIONS AMONG PATIENTS IN EASTERN INDIA","authors":"A. Islam, M. Mondal, C. Datta, U. Chatterjee, A. Dastidar","doi":"10.32677/EJMS.2019.V04.I02.004","DOIUrl":null,"url":null,"abstract":"Background: Lung cancer is one of the most common malignancies in the world. About 80–85% of lung cancers are non-small cell lung cancer (NSCLC). The development of therapeutic agents targeting products of epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) rearrangements has significantly improved survival in patients with NSCLC. Thus, the patients eligible for the treatment should be selected through appropriate molecular tests. Objective: The main objective was to study the distribution of NSCLC and its genetic mutations, in the patients of Eastern India. Methodology: A prospective study was carried out among 228 patients, in a tertiary care hospital of Eastern India during a period of 2 years from January 2016 to January 2018. We have included all the patients who were screened and found to have lug carcinoma. The detailed clinical history of the patients was recorded. We have used techniques such as radiology, histopathology, immunohistochemistry (IHC) and molecular study by FISH technique. Results: Out of 138 cases of NSCLC on histopathology 78 cases (56.7%) were reported as squamous cell carcinoma, 46 cases (33.3%) as adenocarcinoma and 14 cases (10.1%) as NSCLC. IHC was used for categorization of NSCLC cases which showed adenocarcinoma in 4 patients and squamous cell carcinoma in 10 patients. EGFR exon 19 deletion mutation was the predominant mutation in adenocarcinoma. Conclusion: Molecular study for genetic analysis has improved the scope for targeted therapy in Nonsmall cell carcinoma patients, thereby reducing mortality and morbidity in cases of lung carcinoma.","PeriodicalId":386906,"journal":{"name":"Volume 4 Issue 2 Apr - Jun 2019","volume":"17 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Volume 4 Issue 2 Apr - Jun 2019","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32677/EJMS.2019.V04.I02.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Lung cancer is one of the most common malignancies in the world. About 80–85% of lung cancers are non-small cell lung cancer (NSCLC). The development of therapeutic agents targeting products of epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) rearrangements has significantly improved survival in patients with NSCLC. Thus, the patients eligible for the treatment should be selected through appropriate molecular tests. Objective: The main objective was to study the distribution of NSCLC and its genetic mutations, in the patients of Eastern India. Methodology: A prospective study was carried out among 228 patients, in a tertiary care hospital of Eastern India during a period of 2 years from January 2016 to January 2018. We have included all the patients who were screened and found to have lug carcinoma. The detailed clinical history of the patients was recorded. We have used techniques such as radiology, histopathology, immunohistochemistry (IHC) and molecular study by FISH technique. Results: Out of 138 cases of NSCLC on histopathology 78 cases (56.7%) were reported as squamous cell carcinoma, 46 cases (33.3%) as adenocarcinoma and 14 cases (10.1%) as NSCLC. IHC was used for categorization of NSCLC cases which showed adenocarcinoma in 4 patients and squamous cell carcinoma in 10 patients. EGFR exon 19 deletion mutation was the predominant mutation in adenocarcinoma. Conclusion: Molecular study for genetic analysis has improved the scope for targeted therapy in Nonsmall cell carcinoma patients, thereby reducing mortality and morbidity in cases of lung carcinoma.
非小细胞肺癌:印度东部患者的分布和突变谱
背景:肺癌是世界上最常见的恶性肿瘤之一。约80-85%的肺癌是非小细胞肺癌(NSCLC)。针对表皮生长因子受体(EGFR)基因突变和间变性淋巴瘤激酶(ALK)重排产物的治疗剂的开发显著提高了非小细胞肺癌患者的生存率。因此,应通过适当的分子检测选择适合治疗的患者。目的:主要目的是研究非小细胞肺癌及其基因突变在印度东部患者中的分布。方法:在2016年1月至2018年1月的2年间,对东印度一家三级医院的228名患者进行了一项前瞻性研究。我们纳入了所有经过筛查并发现患有肺癌的患者。详细记录患者的临床病史。我们使用了放射学、组织病理学、免疫组织化学(IHC)和FISH技术的分子研究等技术。结果:138例非小细胞肺癌病理报告为鳞状细胞癌78例(56.7%),腺癌46例(33.3%),非小细胞肺癌14例(10.1%)。采用免疫组化法对非小细胞肺癌进行分类,其中腺癌4例,鳞状细胞癌10例。EGFR外显子19缺失突变是腺癌的主要突变。结论:分子遗传学研究扩大了非小细胞癌患者靶向治疗的范围,从而降低了肺癌病例的死亡率和发病率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信